

Curriculum Vitae

Name : **Pallavi Agarwal, PhD**
Designation : Professor /Former DBT-Ramalingaswami Fellow
Affiliation : Amity Institute of Molecular Medicine and Stem Cell Research, Amity University, Noida, Uttar Pradesh, India
Mobile : +91 9871288982
Email ID. : pallaviagarwal29@gmail.com

Specialisation: Cancer biology, Epigenetics, Molecular therapeutics, Cancer diagnosis & Prognosis, Ovarian Cancer, Breast Cancer, Cervical Cancer, Urinary bladder Cancer, Non-invasive Biomarkers, Genomics, transcriptomics & epigenomics, molecular docking, in vitro and in vivo preclinical studies

1. Education

Sl No.	Institution/Place	Degree Awarded	Year	Field of Study
1.	University of Cologne, Cologne, Germany	PhD	2012	Cell & Molecular Biology, Genetics
2.	Devi Ahilya University, Indore, India	Master of Science (M. Sc.)	2004	Industrial Microbiology
3.	Devi Ahilya University, Indore, India	Bachelor of Science (B. Sc.)	2002	Microbiology

2. Position and Employment

Sl No.	Institution Place	Position	From (Date)	To (date)
1.	Amity Institute of Molecular Medicine and Stem Cell Research, Amity University, Noida	Professor	June 21, 2023	Present
2.	Amity Institute of Molecular Medicine and Stem Cell Research, Amity University, Noida	Associate Professor & DBT-Ramalingaswami Fellow	June 22, 2018	June 21, 2023
3.	Amity Institute of Molecular Medicine and Stem Cell Research, Amity University, Noida	Assistant Professor	Oct. 3, 2016	June 21, 2018
4.	University of Cambridge, Gurdon Institute, Cambridge, UK	Postdoctoral Scientist	March 1, 2013	July 31, 2016
5.	University of Cologne, Germany	Postdoctoral Scientist	May 8, 2012	February 28, 2013
6.	University of Cologne, Germany	PhD student	April 1, 2008	May 7, 2012
7.	Lex Orbis Intellectual Property Practice, New Delhi, India	Patent Scientist (Registered Patent Agent No. 1129)	August 1, 2004	August 31, 2007

3. Honors/Awards

- **SERB International Travel Award (GRC conference Italy: 1500 USD)** **2023**
- **ICMR Extramural Ad-hoc Research grant awarded** **2023 – 2026**
  Funded by Indian Council of Medical Research (ICMR), India
- **BRNS-DAE Research grant awarded** **2021 – 2024**
  Funded by Department of Atomic Energy (DAE), India
- **Ramalingaswami Re-entry fellowship** **2018 – 2023**
  Funded by Department of Biotechnology (DBT), India
- **Early Career Research grant** **2018 – 2021**
  Funded by Department of Science & Technology (DST), India
- **Bio-Care Research grant** **2017 – 2021**
  Funded by Department of Biotechnology (DBT), India
- **Dr. DS Kothari Postdoctoral Fellowship** **2017**
  Funded by University Grants Commission (UGC), India (not availed)
- **Postdoctoral funding** **2013 – 2016**
  Funded by Cancer Research UK (CRUK)
- **PhD funding** **2008 – 2012**
  Funded by German Research Foundation (DFG)

4a. Publications

(1) Goyal S, Beniwal SK, **Agarwal P**, Brar RK, Jain P, Kumar HS, Das BC. **(2025)** Efficacy and Safety of Curcumin as an Adjuvant to Standard Chemotherapy in Advanced and Metastatic Breast Cancer Patients: A Randomized Controlled Study. **Phytotherapy Research** Nov;39(11):5006-5024. ***(IF: 8.1)***

(2) Singh I, Karna A, Prajapati A, Solanki U, Mukherjee A, Uppal S, Malhotra P, Kumar M, **Agarwal P (2025)** Epigenetic targeting of MECOM/KRAS axis by JIB-04 impairs tumorigenesis and cisplatin resistance in MECOM-amplified ovarian cancer. **Cell Death Discovery**. Jul 15;11(1):326. ***(IF: 11.1) (*corresponding Author)***

(3) Juhi Mishra, Neelam Poonia, Amarnath Karna, Mamatha Davuluri, Viney Lather, **Pallavi Agarwal**, Deepti Pandita (2025) Garcinol: An emerging epigenetic modifier with versatile anticancer properties. **Letters in Drug Design & Discovery**, 21 July 2025, 22(5):100067 ***(*corresponding Author)***

(4) Sharma HK, Singh I, Karna A, Gupta P, Singh T, Kumar A, Pandita D, Mukherjee M, Parmar VS, **Agarwal P,** Lather V. **(2025)** Counteracting methicillin resistant Staphylococcus aureus through novel Citral-Azithromycin combination. **Scientific Reports**. Jul 15;15(1):25548. ***(IF: 4.9)***

(5) Das A, Grewal AS, **Agarwal P,** Pandita D, Lather V. **(2025)** Maternal Embryonic Leucine Zipper Kinase (MELK) as a Promising Therapeutic Target in Triple Negative Breast Cancer. **Anticancer Agents Med Chem**. May 23. 2025;25(19):1473-1484. ***(IF: 3.0)***

(6) Firuj Ahmed, Hitesh K. Sharma, Monalisa Mukherjee, **Pallavi Agarwal**, Anoop Kumar, Deepti Pandita and Viney Lather **(2025)** Exploring Synergistic Potential of Phytomolecules-Antibiotics Combination Against Escherichia Coli: An Integrated Approach Using Structure Based Drug Design. **Pharmacological Research - Natural Products** March 25, 6: 100160

(7) Nazia Nazam, Iftikhar Ahmad, Nasimudeen R. Jabir, Torki A. Zughaibi, **Pallavi Agarwal,** Ahdab Alsaieedi, Mohd Shahnawaz Khan and Shams Tabrez **(2025)** Deciphering Pharmacological Targets of Plumbagin in Cisplatin-resistant Ovarian Cancer Model using in vitro and in silico Approaches. **Current Pharmaceutical Design** August 27, 202**5;** 32;15: 1183 -1199 ***(IF: 2.8)***

(8) Hitesh K Sharma, Amarnath Karna, Sajendra K Verma, Puneet Gupta, Dheeraj Nagpal, Anoop Kumar, Deepti Pandita, Monalisa Mukherjee, Virinder S Parmar, **Pallavi Agarwal**, Viney Lather **(2025)** Exploring the Synergistic Effect of Thymol with Oxacillin against Methicillin Resistant Staphylococcus aureus. **Indian Journal of Microbiology**. 65, 1828-1837, (2025) ***(IF: 3)***

(9) Nath S and **Agarwal P** (2023), Editorial: Genetic regulation of mitosis and ploidy in cancer. **Frontiers in Genetics**. 14:1264772. (doi: 10.3389/fgene.2023.1264772) ***(IF: 4.77) (*corresponding Author)***

(10) Amiya Das, Anita Prajapati, Amarnath Karna, Hitesh Kumar Sharma, Sheetal Uppal, Viney Lather*, Deepti Pandita*, **Pallavi Agarwal*** (2023) Structure-based virtual screening of chemical libraries as potential MELK inhibitors and their therapeutic evaluation against breast cancer; **Chemico-Biological Interactions** *376, 110443* ***(IF:5.4) (*corresponding Author)***

(11) Amiya Das, Hitesh Kumar Sharma, Viney Lather*, Deepti Pandita* and **Pallavi Agarwal*** (2023) Structure-based virtual screening and therapeutic evaluation of small molecules as CDC20 inhibitors in breast cancer: A drug repurposing approach ***3 Biotech*** *13, 141* ***(IF: 2.9) (*corresponding Author)***

(12) Amiya Das, **Pallavi Agarwal**, Gaurav Kumar Jain, Geeta Aggarwal, Deepti Pandita, Viney Lather (2022) Repurposing drugs as novel triple negative breast cancer therapeutics. **Anti-Cancer Agents in Medicinal Chemistry** 22; 3:515-550. **(IF – 2.55)**

(13) Topno R[$]; Singh I[$]; Kumar M*; **Agarwal P*** (2021) Integrated bioinformatic analysis identifies UBE2Q1 as a potential prognostic marker for high grade serous ovarian cancer; **BMC Cancer** Mar 4;21(1):220. **(IF- 4.4)** ***(*corresponding Author)***

(14) Topno R[$]; Nazam N[$]; Kumari P, Kumar M*; **Agarwal P*** (2021); Integrative genome wide analysis of protein tyrosine phosphatases identifies CDC25C as prognostic and predictive marker for chemoresistance in breast cancer; **Cancer Biomarkers** 2021;32(4):491-504 **(IF- 4.38)** ***(*corresponding Author)***

(15) Amiya Das, Deepti Pandita, Gaurav Kumar Jain, **Pallavi Agarwal**, Ajmer Singh Grewal, Roop Krishen Khar, Viney Lather (2021) Role of phytoconstituents in the management of COVID19. **Chemico-Biological Interactions** 341, 109449 **(IF – 5.4)**

(16) Mehreen Aftab, Satish Poojari, Vaishnavi Seshan, Sachin Kumar, **Pallavi Agarwal**, Simran Tandon, Vijay Zutshi, Bhudev Das (2021) Urine miRNA signature as a potential non-invasive diagnostic and prognostic biomarker in cervical cancer **Scientific Reports** May 14;11: 10323 (**IF – 5.1)**

(17) **Agarwal P,** and Jackson SP. (2016) G9a inhibition potentiates the anti-tumour activity of DNA double-strand break inducing agents by impairing DNA repair independent of p53 status. **Cancer Letters** 16;380(2):467-475 **(IF – 10.1)**

(18) **Agarwal P**, Schulz JN, Blumbach K, Heinegård D, Paulsson M, Mauch C, Eming C, Eckes B, Krieg T. (2013) Enhanced expression of cartilage oligomeric matrix protein is a common feature in fibrotic skin pathologies **Matrix Biology** 32:325–331 **(IF – 11.6)**

(19) Moinzadeh P*, **Agarwal P*,** Bloch W, Poor L, Orteu C, Hunzelmann N, Eckes B and Krieg T. (2013) Systemic sclerosis with multiple nodules: characterization of the extracellular matrix, **Archives of Dermatological Research** 305:645–652 **(IF – 3.0)**

(20) **Agarwal P*,** Zwolanek D*, Keene DR, Schulz JN, Blumbach K, Heinegård D, Zaucke F, Paulsson M, Krieg T, Koch M, Eckes B. (2012) Collagen XII and XIV - new partners of cartilage oligomeric matrix protein in the skin extracellular matrix suprastructure, **Journal of Biological Chemistry** 287(27): 22549-59 **(IF – 5.2)**

(21) Pillai M, Kumar S, Kumar R, **Agarwal P.** (2006) India's Tryst with TRIPS Continues! **Journal of Intellectual Property Rights** 11:53 – 56

4b. Book Chapter

(1) Nazia Nazam, Ravi Teja Chatava, **Pallavi Agarwal** (2019) 'Lactate dehydrogenase: The role in the Warburg effect and Cancer' (*Lactate dehydrogenase (LDH) Biochemistry, Function and Clinical Significance)* USA: **Nova Science Publishers Inc. New York**, 11 **(*corresponding Author)**

(2) Sonia Kapoor, **Pallavi Agarwal**, Amiya Das, Simran Tandon (2023) 'Targeting the tumor microenvironment: Changing the landscape of cancer' (*Molecular Biomarkers in Cancer: Techniques, Discoveries and Translational Applications*) UK: **Cambridge Scholars Publishing Limited**

(3) Rupa Mishra, Priyam Saini, Bhudev C Das**, Pallavi Agarwal** and Manoj Kumar (2026) 'Increasing Efficiency of CRISPR/Cas9 Gene Editing' *(Targeted Nanocarrier-Based CRISPR/Cas9 System for cancer treatment applications)* **CRC Press, Taylor & Francis Group**

(4) Meenakshi Sharma, Mrunal Mhatre, Sanchita Roypradhan, Manoj Kumar and **Pallavi Agarwal** (2026) 'Current Clinical Status for CRISPR/Cas9 in Cancer Therapy' *(Targeted Nanocarrier-Based CRISPR/Cas9 System for cancer treatment applications)* **CRC Press, Taylor & Francis Group (*corresponding Author)**

4c. Abstracts published in Conference Proceeding

(1) Ranjan, M., Jain, P., Singh, I., Kumar, M., Sharma, V., Bargotya, M., **Agarwal, P.**, & Das, BC. 'Urinary microRNA Expression Signatures as Non-Invasive Biomarkers for Predicting Bladder Cancer Progression' abstract is published in ESMO Open journal Supplement: European Society for Medical Oncology (ESMO) Targeted Anticancer Therapies (TAT) Asia Congress 2025, 18–20 July 2025, Hong Kong SAR, China. (IF: 8.3) https://doi.org/10.1016/j.esmoop.2025.105460

(2) Prajapati A, Uppal S, **Agarwal P**; "Unravelling the synergistic effect of histone deacetylase and efflux transporter inhibitors in radio-resistant TNBC cells" Abstracts Published in **ESMO Open** Volume 10: Supplement 4 Abstract book of the ESMO Breast Cancer Congress 2025, 14-17 May 2025, Munich, Germany; Page 12. (IF: 8.3) https://doi.org/10.1016/j.esmoop.2025.104738

(3) Mishra R., Kumar M., Agarwal P., & Das BC; "PIK3CA modulates oncogenic and stemness properties in Cervical Cancer" Abstract Published in Molecular Oncology, Volume 19: Supplement 1: EACR 2025: Innovative Cancer Science, 16-18 June 2025, Lisbon, Portugal, June 2025, Page 1-895. (IF: 5)

(4) Mishra R., Agarwal P., Kumar M., & Das BC; "Targeting the PIK3CA/c-MYC Pathway to Inhibit Oncogenicity and Stemness in Cervical Cancer" Abstracts Published in ESMO Open journal, volume 10: Supplement 6: European Society for Medical Oncology (ESMO) Targeted Anticancer Therapies (TAT) Asia Congress 2025,18–20 July 2025, Hong Kong SAR, China, July 2025. (Impact factor:7.1)

(5) Prajapati A, Uppal S, **Agarwal P;** "Overcoming radiation resistance in triple-negative breast cancer: Synergistic potential of HDAC and ABC transporter inhibitor" Abstracts Published in **ESMO Open** Volume 10: Supplement 2 Abstract book of the ESMO Targeted Anticancer Therapies Congress 2025, 3-5 March 2025, Paris, France; Page 1-2. (IF: 8.3)

(6) Singh I*, Prajapati A, Karna A, Mukherjee A, Uppal S, Malhotra P, Kumar M, **Agarwal P**."E-JIB-04: An epigenetic targeted therapy for ovarian cancer with MECOM amplification" **ESMO Open**, Volume 9, 103896: Molecular Analysis for Precision (MAP) Oncology Congress 2024, 16-18 October 2024, London, UK. (IF: 8.3)

(7) A Karna, K Manoj, **A Pallavi**; "Sirtuin 6 deficiency induces apoptosis in low-H3K9ac expressing ovarian cancer cells via impairing DNA repair and survival pathways" Abstracts Published in **Molecular Oncology** Volume18, Issue S1, Supplement: EACR 2024: Innovative Cancer Science, 10-13 June 2024, Rotterdam, Netherlands June 2024 Pages i-ii, 1-495 (IF: 4.5)

(8) Singh I, Kumar M, **Agarwal P**; "Epigenetic targeting of MECOM dependency in ovarian cancers" Abstracts Published in **Molecular Oncology** Volume 17: Supplement: EACR 2023: Innovative Cancer Science, 12-15 June 2023, Torino, Italy Jun 2023 Pages i-ii, 1-597 (IF: 4.5)

5. Patents Filed

Title of the Invention: "An Anti-Cancer Potential Of 2-(1H-IMIDAZOL-5-YL) Phenol derivatives and Method Thereof" Application No. 202211052774 dated 15 September 2022

6. Research Support

6a. Ongoing Research Projects

Sl. No.	Title of the project	Sanction No. /duration	Total Cost (in Rs.)	Agency	Present status	Role (PI/CI)
1.	Development of Urine based mRNA-surveillance biomarker panel for monitoring recurrence in high grade bladder cancer patients	2021-12632 (March 2023 – 2026)	63,00,000	ICMR	Ongoing	PI
2.	Unravelling role of epigenetic modulators in radiation-induced DNA Damage Response (DDR) and radioresistance pathways	58/14/16/2021-BRNS (Nov 2021 – Nov 2024)	39,06,600	BRNS-DAE	Ongoing	PI
3.	Unravelling oncogenic role of sirtuin 6 in Ovarian cancer (SRF: Mr. Amarnath Karna)	(Awarded) 2020-7968 (2022 – 2025)	12,60,000	ICMR-SRF	On-going	SRF mentor

6b. Completed Research Projects

Sl. No.	Title of the project	Sanction No. /duration	Cost (in Rs.)	Agency	Present status	Role
1.	Identifying new cancer drivers and exploring their transcriptional regulation in ovarian cancers to develop new therapeutic approaches	BT/RLF/Re-entry/16/2016 (2018 – 2023)	1,03,60,000	DBT-Ramalingaswami Fellowship	Completed	PI
2.	Analysis of key gene mutations and miRNAs and their interaction with Fos-related antigen 1/2 (Fra-1/2) to identify therapeutic target(s) in triple negative breast cancer stem cells	2019-0879 (2019 – 2022) (PI: Prof. Das)	79,02,000	ICMR Adhoc	Completed	Co-investigator
3.	Deciphering therapeutic potential of an epigenetic target in ovarian tumorigenesis and	(Awarded) 2020 – 2023	17,52,000	ICMR-RA	Completed	RA mentor

	drug resistance (PDF: Dr. Nazia Nazam)					
4.	Dissecting epigenomics of high-grade serous ovarian cancers to identify new therapeutic targets	ECR/2017/000857 (2018 – 2021)	47,62,560	DST-SERB ECRA	Completed	PI
5.	Understanding epigenetic regulation of chemoresistance pathways in ovarian cancers to develop new therapeutic approaches	BT/PR18554/BIC/101/259/2016 2017 - 2020	38,26,628	DBT-Biocare Extramural Grant	Completed	PI
6.	Study of oncogenic drivers and their transcriptional regulation in ovarian cancers (Student PI – Ibha Singh)	SR/WOS-A/LS-471/2018 (2019 – 2022)	23,49,560	DST-WOSA	Completed	Mentor

7. Professional Experience and Training

- Training in ChIP-Seq and RNA-Seq analysis programs
- Trained in computational and biostatistical data analysis
- Trained in bioinformatics tools Clustal, Expasy, Seqbuilder, ApE, Ensembl, phython

8. Research, Teaching and Administration Experience

8a. Teaching (UG/PG/PGD/PhD)
Trends in Molecular Oncology, Human Genetics & Cytogenetics, Biomarkers & Molecular Diagnostics, Quality Control Biologists, IPR, Bioethics and clinical trials, Oncogenetic counselling

8b. Academic & Administrative activity:

- ✓ *Administrative Coordinator, Faculty Academic Coordinator, Examination Coordinator*
- ✓ *Student Outcome/Assessment Committee Coordinator, Alumni Coordinator, Student Abroad Program Coordinator*
- ✓ *Student Grievance cell member, Admission Interviewer, Faculty Co-coordinator (SynBIO student club)*
- ✓ *Course Coordinator for Various courses, Paper setter/Moderator/Evaluator for various courses, Dissertation/Training Coordinator*
- ✓ *Institutional Committee Members, Doctoral Research Committee, PRoAC & CRC committee, Placement Committee, Institutional Research Committee*

8c. Ph.D./Research Scholar/Postdoctoral Scientist Mentorship

S.No.	Name	Status (Completed/Ongoing)
1.	Dr. Amiya Das (PhD student)	Awarded
2.	Ms. Ibha Singh (DST-WOSA Scientist & PhD student)	Awarded
3.	Mr. Shekhar Goyal (PT PhD student)	ODC held, Awarded
4.	Dr. Viniita Jaggi (Medical Doctor & PT-PhD student)	Ongoing
5.	Dr. Saquib Raza (Medical Doctor & PT-PhD student)	Ongoing
6.	Ms. Anita Prajapati (BRNS – JRF & PhD students)	Ongoing
7.	Ms. Meenakshi (PhD student)	Ongoing
8.	Mallika Ranjan (ICMR-DHR Scientist)	Ongoing

8d. Ph.D./Research Scholar/Postdoctoral Scientist Achievements

(1) Poster Presentation at ESMO Molecular Analysis for Precision (MAP) Oncology Congress 2024, London – Ms. Ibha Singh

(2) Oral Presentation at International Conference on Biology Beyond Borders, Pune Maharashtra – Ms. Ibha Singh and Mr. Amarnath Karna

(3) Poster Presentation at European Association for Cancer Research 2024 at Netherland – Mr. Amarnath Karna

(4) Poster Presentation at European Association for Cancer Research 2023 at Torino, Italy – Ms. Ibha Singh

(5) Oral Presentation at Cell Cycle Conference, Cambridge, UK organised by Abcam – Ms. Ibha Singh

(6) Indian Association for Cancer Research Conference (IACR2022) – Best Poster Award– Ms. Ibha Singh

(7) Indian Association for Cancer Research Conference (IACR2022) – Best Oral Award– Dr. Nazia Nazam

(8) ICMR-SRF awarded in 2022 – Mr. Amarnath Karna

(9) ICMR-RA awarded in 2020 – Ms. Nazia Nazam

(10) DST-WOSA awarded in 2019 – Ms. Ibha Singh

9. Conferences, workshops and meetings attended

S. No.	Name of the Meeting	Venue and Duration	Nature of Participation
1.	Six-Day training Program for Basic learning in Computational Drug Design	All India Institute of Ayurveda, New Delhi December 1 – 6, 2025	Invited Speaker
2.	International Conference on "Viksit Bharat 2047: Reaching the Unreached Through Chemical and Biological Sciences (VBCB-2025)	SRM IST, Ghaziabad Feb 18 – 20, 2025	Invited Speaker
3.	5th International Global Cancer Consortium Conference	AUUP, Noida, India Jan 29 – 31, 2025	Invited Speaker
4.	Gordon Research Conference (2023 Cancer Genetics and Epigenetics) (SERB Travel Grant)	Lucca, Italy May 21 -26, 2023	Poster Presentation
5.	3rd World Congress on Translational Cancer Research and Immunotherapy [WCTCRI-2023]	Mahatma Gandhi Medical College and Hospital, Jaipur, India February 3-5, 2023	Invited Speaker
6.	41st International Annual Conference of Indian Association for Cancer Research (IACR-2022)	Amity University Noida (4 days) March 2 – 5, 2022	Treasurer/Organiser
7.	International Keystone Symposia eSymposia meeting Precision Oncology: Translating Discovery to the Clinic	Virtual mode, June 2021 (availed registration fee waiver for symposium)	Poster Presentation
8.	4 Days Virtual EMBO workshop on Chromatin dynamics and nuclear organization in genome maintenance	Virtual mode, Dec 2020	Participation
9.	39th Annual conference of Indian Association for Cancer Research (Life Member)	Trivandrum, Kerala 2020	Poster presentation
10.	The 6th EMBO Meeting	Birmingham, UK, 2015	Invited Speaker
11.	Young Investigator Meeting, IndiaBioscience	Cambridge, UK 2015	Poster presentation
12.	25th German and British Societies Meeting for Matrix Biology	Oxford, UK 2012	Poster presentation
13.	24th German and British Societies Meeting for Matrix Biology	Germany 2011	Poster presentation
14.	20th European Society for Tissue Repair Congress	Ghent, Belgium 2010	Invited Speaker
15.	XXII FECTS meeting	Davos, Switzerland 2010	Invited Speaker
16.	23rd German and British Societies Meeting for Matrix Biology	Frankfurt, Germany 2010	Invited Speaker

10. Conferences, workshops and meetings organized

S.No.	Name of the meeting/Conference	Venue and Duration	Role
1.	International Brain Research Organisation (IBRO)- APRC Sponsored Workshop On Neuro-Pharmaco-Behavioural Studies Using Cell-Culture And Acute As Well As Chronic Animal Models,	AINN, Amity Noida, November 3-7, 2025	Resource Personnel
2.	41st International Annual Conference of Indian Association for Cancer Research (IACR-2022)	Amity University Noida (4 days) March 2 – 5, 2022	Treasurer and Core organising Committee member

3.	Hands on workshop on CRISPR/Cas system for Genome Engineering July 3 – 5, 2019	Amity University (3 days)	Organising member
4.	Hands on Workshop on Molecular Biology Techniques & Stem Cells in Human Health and Diseases	AIMMSCR, Amity University (5 days) June 12-16, 2017	Convenor
	Symposium on Gene Editing & NGS Nov. 30th, 2016	AIMMSCR, Amity University (1 day)	Convenor

11. Membership in Scientific & Academic Societies/Review Panel

S.No.	Name of the Scientific & Academic Societies/Review Panel	Role
1.	Indian Association for Cancer Research, India	Life time member
2.	Indian Society of Cell Biology, India	Life time member
3.	World Society of Interdisciplinary Anti-Aging Medicine (WOSIAM), Paris	Life time member

12. Editorial board member/reviewer of scientific journals

S.No.	Name of the Journal	Role
1.	Cancer Letters (ScienceDirect)	Reviewer
2.	Journal of Cell Communication and Signalling (Nature Springer)	Reviewer
3.	Scientific Report (Nature)	
4.	BMC Cancer (Nature Springer)	Reviewer
5.	Human Cell (Elsevier)	Reviewer
6.	Bioscience Reports (Portland Press)	Reviewer
7.	BMC Complementary and Alternative Medicine (Nature Springer)	Reviewer
8.	Molecular Oncology (Elsevier)	Reviewer
9.	Discover Oncology (Springer Nature)	Reviewer
10.	Frontiers of Genetics	Associate Editor